A5057469165- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- T-cell and B-cell Immunology
- Gastrointestinal Bleeding Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Biosimilars and Bioanalytical Methods
- Eosinophilic Esophagitis
Roche (Switzerland)
2020
Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program ulcerative colitis (UC) and Crohn's disease ongoing will evaluate efficacy safety etrolizumab well-defined patient populations rigorous trials include direct head-to-head comparisons against approved anti-tumor necrosis factor alpha agents (anti-TNF). The consists six randomized controlled (RCTs; UC: HIBISCUS I II, GARDENIA, LAUREL, HICKORY;...
BACKGROUND: Etrolizumab, a humanized anti-β7 monoclonal antibody currently undergoing Phase 3 evaluation in ulcerative colitis (UC) and Crohn's disease (CD), was demonstrated to be well tolerated efficacious patients with moderate severe UC the 2 trial EUCALYPTUS. BERGAMOT (NCT02394028), study, designed sequential induction cohorts single maintenance cohort evaluate safety efficacy of etrolizumab CD. This abstract describes results for exploratory 300 patients. METHODS: Eligible CD...